未登录

L

Lawrence T. Park

national institutes of health (nih) - usa

H指数:22

被引数:2,754

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Inflammation, stress and depression: An exploration of ketamine's therapeutic profile

DRUG DISCOVERY TODAY

IF7.5

2023-04-0123

OAAI

Prospective association of psychological pain and hopelessness with suicidal

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2022-07-0112

OAAI

Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration

TRANSLATIONAL PSYCHIATRY

IF6.2

2022-05-0216

OAAI

The relationship between the HDRS insomnia items and polysomnographic (PSG) measures in individuals with treatment-resistant depression

JOURNAL OF PSYCHIATRIC RESEARCH

IF3.2

2022-04-018

OAAI

The mental health impact of contact with COVID-19 patients on healthcare workers in the United States

PSYCHIATRY RESEARCH

IF3.9

2022-02-015

OAAI

Authors' Reply to Pappagallo et al.: Comment on Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status

IF7.4

2022-01-110

OA

Reply to: Letter to the Editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of Lightnessare not the same - A comment on Acevedo-Diaz et al. (Jpsychiatrres-D-21-00121)

JOURNAL OF PSYCHIATRIC RESEARCH

IF3.2

2021-05-010

OAAI

Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status

IF7.4

2021-04-26102

OAAI

Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2021-02-0118

OAAI

The effects of ketamine on typical and atypical depressive symptoms

Acta Psychiatrica Scandinavica

IF5

2020-08-0618

OAAI

Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression (vol 45, pg 861, 2020)

NEUROPSYCHOPHARMACOLOGY

IF7.1

2020-05-062

OAAI

Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression

NEUROPSYCHOPHARMACOLOGY

IF7.1

2020-04-0667

OAAI

Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2020-02-0170

OAAI

The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response

MOLECULAR PSYCHIATRY

IF10.1

2019-11-1557

OAAI

Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues

IF3.6

2019-11-0134

OAAI

Depression in the Primary Care Setting

NEW ENGLAND JOURNAL OF MEDICINE

IF78.5

2019-02-07260

OAAI

Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration

BIOLOGICAL PSYCHIATRY

IF9

2018-10-01123

OAAI

Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression

JOURNAL OF AFFECTIVE DISORDERS

IF4.9

2018-05-0196

OAAI

Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects

MOLECULAR PSYCHIATRY

IF10.1

2018-02-27150

OAAI

Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion

BIOLOGICAL PSYCHIATRY

IF9

2017-09-0123

OAAI